News

GM-soy: A doubt  follows a yes
Enlarge image

Agri-biotechItalyGermanyEU

GM-soy: A doubt follows a yes

25.06.2012 - A European authority says Monsanto's roundup-ready soy is safe for man and environment. But there is doubt remaining.

Parma/Munich – For the first time, the European Food Safety Authority (EFSA) has approved the cultivation of genetically modified (GM) soy. So far, the  GM soy "roundup-ready" by US-industry leader Monsanto can only be imported to the EU. The Scientific Opinion published by the EFSA’s GMO panel now paves the way for EU Commissioner John Dalli. The Commission can give Monsanto the green light for cultivating the crop on European soils if the EU member states will not achieve a qualified majority on the issue.

However, there might be a fierce head wind blowing. German anti-GMO association Testbiotech e.V. points out that there's a legal minefield in the way. A study done on behalf of Testbiotech says that an expected admittance might violate EU law. Matter of concern: the EFSA opinion itself. According to the study, the EFSA should have also tested if the residues of pesticides to be used (in this case glyphosate) could have negative effects on human health. Not implementing this concern in the risk assessment could be equivalent to a breach of EU laws. The crop in question is soybean 40-3-2. It carries a gene that makes it tolerant to glyphosate (brand name: Roundup). That is why the soybean is also dubbed "roundup-ready soy". The EFSA opinion clearly regulates the use of this pesticide: "It should result in similar or reduced environmental impacts compared with conventional soybean cultivation." The panel also recommends that case-specific monitoring of (1) changes in weed community diversity; and (2) the evolution of resistance to glyphosate in weeds should be deployed.

http://www.european-biotechnology-news.com/news/news/2012-02/gm-soy-a-doubt-follows-a-yes.html

ResearchEUUK

27.07.2016 In view of the Brexit, research academies across Britain are calling for a “bold commitment” from the government. The Royal Society President urges the UK government to underwrite the research of British scientists applying for EU funding.

FinancingBelgium

20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.

Stock marketsFranceEU

19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.

ResearchUK

18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.

M&AUKSwitzerland

13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.

R&DAustriaFrance

12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.

M&AFranceEU

07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.

Prenatal DiagnosticsEUUK

06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.

GenericsSpainGermanyEU

04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.

Drug discoveryUKSwitzerland

30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NEWRON (CH)18.50 CHF9.14%
  • GENMAB (DK)1210.00 DKK5.68%
  • VALNEVA (F)2.42 EUR5.68%

FLOP

  • KAROLINSKA (S)7.30 SEK-3.95%
  • BIOTIE THERAPEUTICS (FI)0.27 EUR-3.57%
  • SAREUM HOLDINGS (UK)0.60 GBP-3.23%

TOP

  • THERAMETRICS (CH)0.05 CHF66.7%
  • PROTHENA PLC (IE)51.61 USD52.6%
  • FLAMEL TECHNOLOGIES (F)12.71 USD34.6%

FLOP

  • MOLOGEN (D)1.80 EUR-28.9%
  • EVOCUTIS (UK)0.04 GBP-20.0%
  • SAREUM HOLDINGS (UK)0.60 GBP-20.0%

TOP

  • KARO BIO (S)31.10 SEK1893.6%
  • NICOX (F)11.17 EUR469.9%
  • SAREUM HOLDINGS (UK)0.60 GBP160.9%

FLOP

  • BB BIOTECH (D)44.69 EUR-84.0%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.87 SEK-77.7%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 26.07.2016